(Q46592694)

23 December 2017

title

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation (English)

1 reference

23 December 2017

1 reference

10

Hołowiecki J

1 reference

23 December 2017

Sebastian Giebel

3

object named as

Giebel S

1 reference

23 December 2017

author name string

Zaucha JM

1

1 reference

23 December 2017

Prejzner W

2

1 reference

23 December 2017

Gooley TA

4

1 reference

23 December 2017

Szatkowski D

5

1 reference

23 December 2017

Kałwak K

6

1 reference

23 December 2017

Wojnar J

7

1 reference

23 December 2017

Kruzel T

8

1 reference

23 December 2017

Balon J

9

1 reference

23 December 2017

Hellmann A

11

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

23 December 2017

Bone Marrow Transplantation

published in

1 reference

23 December 2017

volume

36

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

417-424

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705087

exact match

0 references

cites work

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Imatinib treatment: specific issues related to safety, fertility, and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Practical management of patients with chronic myeloid leukemia receiving imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Effects of imatinib on bone marrow engraftment in syngeneic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

inferred from DOI database lookup

7 January 2021

based on heuristic

Hepatocyte transplantation: emerging insights into mechanisms of liver repopulation and their relevance to potential therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705087

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.BMT.1705087

1 reference

23 December 2017

Dimensions Publication ID

0 references

1 reference

23 December 2017